ArticleAnnals of the rheumatic diseases2022
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome.
Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Exploring microRNA signatures in pediatric non-infectious uveitis: meta-analysis and molecular profiling of patient samples.Journal of applied genetics · 2025Pooled it
- Subclinical atherosclerosis in Behcet's disease and its inverse relation to azathioprine use: an updated meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Pooled it
- Treat-to-target in Behçet syndrome.Nature reviews. Rheumatology · 2026Review
- Cardiac involvement in Behçet's syndrome: findings from a clinically driven cardiological evaluation.Rheumatology (Oxford, England) · 2026Article
- Redistribution of peripheral blood immune cell subsets and remodeling of intercellular communication in rare Behçet's disease: a single-cell transcriptomics study.Frontiers in medicine · 2026Article
- Epigenetic regulation of thrombo-inflammation in Behçet and antiphospholipid syndrome.Journal of translational autoimmunity · 2025Article
- Identification of immune-associated genes and single-cell sequencing analysis in diagnosing Behçet's disease.Scientific reports · 2025Article
- Mendelian randomization analysis and molecular mechanism study of childhood asthma and obstructive sleep apnea.Human genetics · 2025Article
- MiR-425-5p intervenes in autoimmune myocarditis by regulating Treg cell differentiation through NRAS.Frontiers in cell and developmental biology · 2025Article
- Biological disturbance of MiR-425 and its application prospects in cardiovascular diseases.Frontiers in cell and developmental biology · 2025Review
- Expression Levels and Clinical Values of miR-195, miR-424, miR-10b, miR-103a-3p, and miR-542-3p in Vasculo-Behçet's Disease.Mediterranean journal of rheumatology · 2024Article
- Behçet's syndrome: recent advances to aid diagnosis.Clinical and experimental medicine · 2023Review
- The role of miRNAs in Behçet's disease.Frontiers in immunology · 2023Review
- The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma.Open medicine (Warsaw, Poland) · 2023Article
- Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer.Frontiers in immunology · 2023Review
- Erythrocyte oxidative stress and thrombosis.Expert reviews in molecular medicine · 2022Review
- Global alteration of colonic microRNAome landscape associated with inflammatory bowel disease.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBehçet's syndrome (BS) is a rare systemic vasculitis often complicated by thrombotic events. Given the lack of validated biomarkers, BS diagnosis relies on clinical criteria.In search of novel biomarkers for BS diagnosis, we determined the profile of plasmatic circulating microRNAs (ci-miRNAs) in patients with BS compared with healthy controls (HCs).
methodsci-miRNA profile was evaluated by microarray in a screening cohort (16 patients with BS and 18 HCs) and then validated by poly(T) adaptor PCR (PTA-PCR) in a validation cohort (30 patients with BS and 30 HCs). Two disease control groups (30 patients with systemic lupus erythematosus (SLE) and 30 patients with giant cell arteritis (GCA) were also analysed.
resultsFrom the microarray screening, 29 deregulated (differentially expressed (DE)) human ci-miRNAs emerged. A hierarchical cluster analysis indicated that DE ci-miRNAs clearly segregated patients from controls, independently of clinical features. PTA-PCR analysis on the validation cohort confirmed the deregulation of miR-224-5p, miR-206 and miR-653-5p. The combined receiver operating characteristic (ROC) curve analyses showed that such ci-miRNAs discriminate BS from HCs (and BS with active vs inactive disease), as well as BS from patients with SLE and GCA.The functional annotation analyses (FAAs) showed that the most enriched pathways affected by DE ci-miRNAs (ie, cell-matrix interaction, oxidative stress and blood coagulation) are related to thrombo-inflammatory mechanisms. Accordingly, the expression of the three ci-miRNAs from the validation cohort significantly correlated with leucocyte reactive oxygen species production and plasma lipid peroxidation.
conclusionsThe ci-miRNA profile identified in this study may represent a novel, poorly invasive BS biomarker, while suggesting an epigenetic control of BS-related thrombo-inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.